Novo Nordisk A/S vs Royal Caribbean Cruises Ltd — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Royal Caribbean Cruises Ltd trades at $286.28 (market cap $76.75B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Royal Caribbean Cruises Ltd's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RCL | |
|---|---|---|
Market Cap | $220.53B | $76.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $365.84 |
52-Week Low | $35.29 | $246.71 |
Enterprise Value | $239.49B | $98.03B |
Dividend Yield | 3.63% | 1.75% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →